BriaCell Therapeutics Corp. develops immunotherapies for the treatment of cancer. Its lead candidate, Bria-IMT, is in Phase I/IIa clinical trials for the treatment of breast cancer. The company has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, personalized immunotherapy for advanced breast cancer, and BriaDx, a diagnostic test. BriaCell Therapeutics is headquartered in West Vancouver, Canada.